Edesa Biotech, Inc. announced that it has completed enrollment of more than 75% of the patients planned for the primary cohort of a Phase 2b clinical study evaluating the company's drug candidate, designated EB01, as a monotherapy for chronic allergic contact dermatitis. The double-blind, placebo-controlled study is evaluating the safety and efficacy of 2.0% EB01 cream in approximately 170 evaluable subjects in total. In addition to the primary cohort, the company is preparing to initiate the exploratory, dose-ranging component of the study, which will separately evaluate lower-strength concentrations of EB01 in an additional 40 subjects. The company noted that telehealth options and expanded recruitment efforts have helped investigators reach new patient populations and bolster enrollment, despite pandemic-related disruptions. Due to physician and patient interest, the company has also added a voluntary open-label extension for study patients once they complete their treatment in the main study. This guarantees that participants in the placebo arm have access to treatment with the active ingredient. The open label extension is also designed to provide longer term usage data, since allergic contact dermatitis (ACD) often reoccurs, or is chronic.